Compare Citius Pharmaceuticals Inc (CTXR) vs DuPont de Nemours Inc (DD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs DuPont de Nemours Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while DuPont de Nemours Inc trades at $130.71 (market cap $17.89B). The key difference: DuPont de Nemours Inc is far larger — about 1313.5× Citius Pharmaceuticals Inc's market cap, and DuPont de Nemours Inc pays a 1.81% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and DuPont de Nemours Inc for 89 Days on average.
| CTXR | DD | |
|---|---|---|
Market Cap | $13.62M | $17.89B |
Volume | 132,438 | 816,409 |
Sector | Health | Basic Materials |
52-Week High | $1.82 | $154.59 |
52-Week Low | $0.48 | $92.49 |
Typical Hold Time | 16 Days | 89 Days |
Enterprise Value | $3.79M | $19.28B |
Dividend Yield | — | 1.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
DuPont (DD) trades at $131.08, down 1.65% on the day, with a neutral technical signal and mixed fundamentals. Recent earnings have consistently beaten estimates, but 2025 saw a net loss of $779 million on revenue of $6.85 billion. The company maintains innovation with new product launches like the Sugar Separation Advisor and Tyvek with Renewable Attribution, while facing headwinds from legal settlements and uneven demand.
The outlook is cautious; analyst consensus is bullish with a 58.54% buy rating but a price target of $95.00 below the current price. Key opportunities include margin expansion in growth markets, while risks involve PFAS litigation costs, volatile cash flows, and execution challenges in a competitive landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About DuPont de Nemours Inc
DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the electronics and communication, automotive, construction, safety and protection, and water management industries. DuPont benefits from the ability to produce patented specialty chemicals that command pricing power. Noteworthy products include Kevlar, Tyvek, and Nomex have evolved over time to enable a wide range of applications across multiple industries.
Read more on DD →
